ArticleClinical, cosmetic and investigational dermatology2026
Successful Treatment of Refractory Chronic Spontaneous Urticaria with Stapokibart After Omalizumab Failure: A Case Report.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic spontaneous urticaria (CSU) is a mast cell-mediated skin disease characterized by wheals and/or angioedema. Some patients remain symptomatic despite standard-of-care antihistamines or omalizumab. We report a 44-year-old female with refractory CSU with a history of recurrent widespread erythema and wheals with pruritus for over one year. She was failed to achieve adequate disease control with oral antihistamines and 5 doses of omalizumab 300 mg. She was subsequently treated with anti-IL-4Rα antibody stapokibart 300 mg (loading dose 600 mg) for 35 weeks, with an extended-interval dosing regimen (every 2 week for 9 doses, every 3 weeks for 3 doses, and every 6 weeks for 2 doses). Rapid symptom control was observed by week 2 (Urticaria Activity Score [UAS7] of 0 and Urticaria Control Test [UCT] score of 12), with complete disease control achieved by week 22 (UAS7 of 0 and UCT score of 16). No relapse occurred during 3-month follow-up period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.